Health Canada Approves Otsuka & Lundbeck’s Abilify Asimtufii® Long-Acting Injection For Adult Schizophrenia & Bipolar I Maintenance

Health Canada has issued a notice of compliance to Otsuka Canada Pharmaceutical Inc. (OCPI) and Lundbeck Canada Inc. (Lundbeck) approving the use of their long-acting injectable (LAI) antipsychotic Abilify Asimtufii® (aripiprazole prolonged-release injectable suspension) as a once-every-two-months treatment for schizophrenia and as maintenance monotherapy for bipolar I disorder in adults. The medication can be used without the need to establish treatment adequacy with a shorter-acting LAI.

OCPI commercializes Otsuka medicines in Canada. OCPI focuses on neuroscience, cardio-renal, and nephrology medications. OCPI was established in 2010; it is part of Otsuka Pharmaceutical Co., Ltd . . .